58 results about "Drug availability" patented technology

Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

An implantable drug delivery apparatus for delivering a drug into a bodily fluid in a bodily cavity of a patient over a period of time includes a drug supply reservoir to supply drug into a delivery channel and an actuator for delivering the drug to a predetermined location in the bodily cavity of the patient, such as, for example, a cochlea of a human ear. The drug is loaded into the delivery channel while producing substantially negligible flow at an outlet of the delivery channel.

A patient care management system for assisting a physician in monitoring drug use by a patient. The system receives drug dispensation data for a drug, on the basis of which the system determines drug supply availability data. The drug supply availability data is indicative of periods of time during which the drug was available in non-duplicate supply, or in oversupply, or in insufficient supply. The periods of time are displayed with respect to a common time base. Each degree of supply availability is visually displayed via a graphical user interface using, e.g., a color coded scheme, so as to be distinguishable by a user. This allows a physician to rapidly assess over-consumption or compliance problems. Plural drugs may be monitored on a single display screen. The system may also be adapted to allow an prescribing physician to assess refill compliance, hospitalization periods and prescription drug costs.

A drug supply system for CED (convection-enhanced delivery) catheter infusions is provided, the system including a drug conducting system having a drug depot and a catheter supply line and a conveying device that provides for conveying the drug from the drug depot into the catheter supply line. The drug conducting system is a system that is closed to the outside in a fluidic seal The drug supply system further includes a conveying fluid conveying system arranged between the conveying device and the drug supply system and is connected to the conveying device and to the drug depot, via a drug displacement element, without fluid-drug contact.

A healthcare risk index is generated using a patient or individual's pharmacy claims. The index may be used to explain and predict variation in pharmacy-related costs and variation in total healthcare costs or utilization. In particular, the index is generated by first examining the individual's pharmacy claims to identify any chronic conditions possessed by the individual. Similarly, the individual's pharmacy claims are examined to identify any compliance medications prescribed to the individual. The chronic condition information is used to generate a chronic condition score by summing regression coefficients for each chronic condition possessed by the individual. Likewise, the compliance medication information is used to generate a compliance medication score by summing products of regression coefficients for each compliance medication prescribed to the individual with associated medication supply weights. From there, a modified chronic condition score is generated by multiplying the chronic condition score by an overall chronic condition regression coefficient. The modified chronic condition score may then be further modified by subtracting a no-claims weight from the chronic condition score in cases where the individual has no pharmacy claims. Finally, the risk index may be determined by summing the modified chronic condition score and the compliance medication score.

A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture.

The invention relates to a delivery device for nasal medication. It addresses need for delivering medication to the nose of a patient. In a preferred embodiment the device has: •A transducer 10 adapted to create an ultrasonic focal zone; •a feeder chamber 13 holding medication; •an energising chamber 14 smaller than the feeder chamber; •a mesh 15; and •an exit 17. The device is formed so that when it is activated the feeder chamber 13 continuously fills the energising chamber 14 with medication (until the feeder chamber has insufficient medication left to achieve this) so that there is a substantially constant supply of medication within the focal zone able to be energised and forced from the energising chamber so as to contact the mesh, become an aerosol, and leave the device by way of the exit.

The invention relates to an ofloxacin molecular inclusion nanometer preparation and a preparation method thereof, belonging to the technical field of medicines. The main raw materials of the molecular inclusion nanometer preparation are cyclodextrin, solubilizer, polymer materials, ofloxacin and the like. The preparation method comprises the steps of: adding the cyclodextrin after dissolving the ofloxacin in a solution containing the solubilizer and preparing a molecular inclusion compound through a gradient ultrasonic grinding method; then adding the polymer materials for grinding; and drying and smashing to obtain the ofloxacin molecular inclusion nanometer preparation. The average particle size of the molecular inclusion nanometer preparation is 252.3 nm; and the drug content is 1%-25%. The preparation method, disclosed by the invention, has the advantages of being simple in a preparation process, high in drug carrying amount and stability, controllable in quality, suitable for industrial production and the like. The ofloxacin molecular inclusion nanometer preparation prepared by the method has the advantages of efficiently improving stability of the drug and dissolution degree as well as dissolution speed of the drug in a gastrointestinal tract, improving a drug absorption rate, realizing rapid and efficient effects, masking bitter taste of the drug, reducing drug irradiation and improving drug palatability and drug availability.